MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

Search

Grifols SA

Ouvert

SecteurFinance

8.63 -6.2

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.326

Max

9.308

Chiffres clés

By Trading Economics

Revenu

17M

69M

Ventes

183M

2B

P/E

Moyenne du Secteur

45.229

22.015

BPA

0.101

Marge bénéficiaire

3.491

Employés

23,833

EBITDA

57M

482M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+72.24% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

3.3B

6.8B

Ouverture précédente

14.83

Clôture précédente

8.63

Sentiment de l'Actualité

By Acuity

65%

35%

484 / 542 Classement par Finance

Score Technique

By Trading Central

Confiance

Neutral Evidence

Grifols SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 avr. 2025, 17:19 UTC

Acquisitions, Fusions, Rachats

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2 avr. 2025, 13:02 UTC

Acquisitions, Fusions, Rachats

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2 avr. 2025, 10:13 UTC

Acquisitions, Fusions, Rachats

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

8 juil. 2024, 10:40 UTC

Acquisitions, Fusions, Rachats

Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker

8 juil. 2024, 09:13 UTC

Acquisitions, Fusions, Rachats

Grifols Faces Delisting Bid From Founding Family and Brookfield

2 avr. 2025, 09:27 UTC

Actions en Tendance

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Comparaison

Variation de prix

Grifols SA prévision

Objectif de Prix

By TipRanks

72.24% hausse

Prévisions sur 12 Mois

Moyen 14.02 EUR  72.24%

Haut 19.05 EUR

Bas 11 EUR

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

2

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

8.152 / 8.574Support & Résistance

Court Terme

Neutral Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

484 / 542Classement par Finance

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.